Treat Large and Small Airway Inflammation
QVAR® is an inhaled corticosteroid (ICS) indicated for patients with persistent asthma.1 QVAR® is a small-particle ICS— mean particle size is 1.1µm—that reaches and treats chronic inflammation in both the large and small airways.2-4*
The small airways in the lungs can be sites of chronic inflammation in patients with persistent asthma.2 If untreated, they may undergo irreversible structural changes.2,5 Treating inflammation in the small airways may improve lung function and contribute to asthma control.2
* The relationship of particle size to clinical efficacy is unknown.
Precise Asthma Control With QVAR®
QVAR® is distributed through large and small airways,* achieving lung deposition of up to 58%.3 Even patients with poor inhaler technique can achieve more than 30% lung deposition.3
Discover the QVAR® Difference
QVAR® is the only small-particle ICS indicated for children as young as 5 years old.1,6 It also has a low rate of oropharyngeal side effects,1,6 can be used with or without a spacer,1 and is covered by most insurance plans7—making it a good choice for a wide range of patients.
QVAR® (beclomethasone dipropionate HFA) Inhalation Aerosol is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age or older. QVAR® is also indicated for asthma patients who require systemic corticosteroid administration, where adding QVAR® may reduce or eliminate the need for systemic corticosteroids.
Important Safety Information
QVAR® is not a bronchodilator and is not indicated for relief of acute bronchospasm.
CAUTION: Adrenal insufficiency may occur when transferring patients from systemic steroids (see WARNINGS, Prescribing Information).
A reduction in growth velocity in growing children and teenagers may occur as a result of inadequate control of chronic diseases such as asthma or from use of corticosteroids for treatment
Common side effects associated with the use of QVAR® and placebo in clinical trials include, but are not limited to, headache (12% and 9% respectively) and pharyngitis (8% and 4% respectively).